Patients treated with Pt-based anticancer drugs (PtII) often experience severe side effects
and are susceptible to cancer recurrence due to the limited bioavailability of PtII and tumor …

To develop next-generation metal drugs with high efficiency and low toxicity for targeting
inhibition of gastric tumor growth and metastasis, we not only optimized a series of …

Platinum-based drugs are widely used in chemotherapy for various types of cancer and are
considered crucial. Tetravalent platinum (Pt (IV)) compounds have gained significant …

Abstract Introduction Natural products (NPs) play a crucial role in the development of
therapeutic drugs. However, it is still highly challenging to identify the targets of NPs …

Chemotherapy remains the primary treatment method for osteosarcoma after surgery.
However, the lack of selectivity of chemotherapy for osteosarcoma leads to unpredictable …

Platinum-based chemotherapeutics are widely used for cancer treatment but are frequently
limited because of dosage-dependent side effects and drug resistance. To attenuate these …

Developing multitarget platinum (IV) prodrugs is an important strategy to attenuate cisplatin
(CDDP) resistance in tandem with reduced toxicity. Herein, six novel ligustrazine-derived …

To ameliorate the defects including serious side effects and drug resistance of Pt (II) drugs
(eg, cisplatin and oxaliplatin), here a novel of “dual-prodrug” by containing Pt (II) drugs and …

Background Cancer continues to be a prominent issue in the field of medicine, as
demonstrated by recent studies emphasizing the significant role of autophagy in the …

Although cisplatin has been widely used for clinical purposes, its application is limited due to
its obvious side effects. To mitigate the defects of cisplatin, here, six “multitarget prodrugs” …